These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28350209)

  • 61. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
    Chapuy B; Schuelper N; Panse M; Dohm A; Hand E; Schroers R; Truemper L; Wulf GG
    Br J Haematol; 2011 Feb; 152(4):401-12. PubMed ID: 21689083
    [TBL] [Abstract][Full Text] [Related]  

  • 62. miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma.
    Fuertes T; Ramiro AR; de Yebenes VG
    Trends Immunol; 2020 Oct; 41(10):932-947. PubMed ID: 32888820
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Selective Termination of Autophagy-Dependent Cancers.
    Roy A; DePamphilis ML
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994949
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
    Drewry DH; Potjewyd FM; Bayati A; Smith JL; Dickmander RJ; Howell S; Taft-Benz S; Min SM; Hossain MA; Heise M; McPherson PS; Moorman NJ; Axtman AD
    J Med Chem; 2022 Oct; 65(19):12860-12882. PubMed ID: 36111834
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL.
    Smith SD; Gopal AK
    J Clin Oncol; 2021 May; 39(15):1671-1673. PubMed ID: 33861621
    [No Abstract]   [Full Text] [Related]  

  • 66. Targeting PI3K-Gamma in Non-Hodgkin Lymphoma.
    Fruman DA
    J Clin Oncol; 2019 Apr; 37(11):932-934. PubMed ID: 30811291
    [No Abstract]   [Full Text] [Related]  

  • 67. PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders.
    Huang PT; Einav S; Asquith CRM
    Nat Rev Drug Discov; 2021 Oct; 20(10):730. PubMed ID: 34504321
    [No Abstract]   [Full Text] [Related]  

  • 68. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.
    Nelson EA; Dyall J; Hoenen T; Barnes AB; Zhou H; Liang JY; Michelotti J; Dewey WH; DeWald LE; Bennett RS; Morris PJ; Guha R; Klumpp-Thomas C; McKnight C; Chen YC; Xu X; Wang A; Hughes E; Martin S; Thomas C; Jahrling PB; Hensley LE; Olinger GG; White JM
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005540. PubMed ID: 28403145
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis.
    Sergin I; Evans TD; Zhang X; Bhattacharya S; Stokes CJ; Song E; Ali S; Dehestani B; Holloway KB; Micevych PS; Javaheri A; Crowley JR; Ballabio A; Schilling JD; Epelman S; Weihl CC; Diwan A; Fan D; Zayed MA; Razani B
    Nat Commun; 2017 Jun; 8():15750. PubMed ID: 28589926
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting personalized medicine in a non-Hodgkin lymphoma patient with 18F-FDG and 18F-choline PET/CT.
    Ribeiro TH; S R; Castro AC; Paulino E; Mamede M
    Rev Assoc Med Bras (1992); 2017 Feb; 63(2):109-111. PubMed ID: 28355370
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Snx10 and PIKfyve are required for lysosome formation in osteoclasts.
    Sultana F; Morse LR; Picotto G; Liu W; Jha PK; Odgren PR; Battaglino RA
    J Cell Biochem; 2020 Apr; 121(4):2927-2937. PubMed ID: 31692073
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.
    Ikonomov OC; Sbrissa D; Shisheva A
    Toxicol Appl Pharmacol; 2019 Nov; 383():114771. PubMed ID: 31628917
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.
    Kang YL; Chou YY; Rothlauf PW; Liu Z; Soh TK; Cureton D; Case JB; Chen RE; Diamond MS; Whelan SPJ; Kirchhausen T
    Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20803-20813. PubMed ID: 32764148
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.
    Kang YL; Chou YY; Rothlauf PW; Liu Z; Soh TK; Cureton D; Case JB; Chen RE; Diamond MS; Whelan SPJ; Kirchhausen T
    bioRxiv; 2020 Jun; ():. PubMed ID: 32511398
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of PIKfyve kinase as a target in multiple myeloma.
    de Campos CB; Zhu YX; Sepetov N; Romanov S; Bruins LA; Shi CX; Stein CK; Petit JL; Polito AN; Sharik ME; Meermeier EW; Ahmann GJ; Armenta IDL; Kruse J; Bergsagel PL; Chesi M; Meurice N; Braggio E; Stewart AK
    Haematologica; 2020 Jun; 105(6):1641-1649. PubMed ID: 31582538
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis.
    Sharma G; Guardia CM; Roy A; Vassilev A; Saric A; Griner LN; Marugan J; Ferrer M; Bonifacino JS; DePamphilis ML
    Autophagy; 2019 Oct; 15(10):1694-1718. PubMed ID: 30806145
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
    Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
    PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation.
    Ikonomov OC; Altankov G; Sbrissa D; Shisheva A
    Toxicol Appl Pharmacol; 2018 Oct; 356():151-158. PubMed ID: 30098992
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PIKfyve regulates melanosome biogenesis.
    Liggins MC; Flesher JL; Jahid S; Vasudeva P; Eby V; Takasuga S; Sasaki J; Sasaki T; Boissy RE; Ganesan AK
    PLoS Genet; 2018 Mar; 14(3):e1007290. PubMed ID: 29584722
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.